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32 Abbreviations 
ACS             acute coronary syndrome 
AMI             acute myocardial infarction 
AP                angina pectoris 
CABG          coronary artery bypass grafting surgery 
CAM            cellular adhesion molecule 
CHD             coronary heart disease 
CRP              C-reactive protein 
CVD             cardiovascular disease 
HDL             high density lipoprotein 
ICAM-1       intercellular adhesion molecule 1  
IL-1ȕ            interleukin 1ȕ
IL-6              interleukin 6
IL-8              interleukin 8 
IL-10            interleukin 10 
LDL             low density lipoprotein 
LVEF           left ventricular ejection fraction 
mBMC         mononuclear bone marrow cells 
MCP-1         monocyte chemoattractant protein 1 
MMP            matrix metalloproteinase 
MRI              magnetic resonance imaging 
NSTEMI      non-ST-elevation myocardial infarction 
PAD             peripheral arterial disease 
PCI               percutaneous coronary intervention 
sCD40L        soluble CD40 ligand 
SMC             smooth muscle cell 
STEMI         ST-elevation myocardial infarction 
TGFȕ           transforming growth factor ȕ
TIMP-1        tissue inhibitor of metalloproteinases 1 
TNFD           tumor necrosis factor D
VCAM-1      vascular cellular adhesion molecule 1  
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54  General introduction 
4.1 Atherosclerosis 
4.1.1 Epidemiology and classification 
Atherosclerosis is by far the most frequent underlying cause of cardiovascular disease (CVD) 
which accounts for about 50% of all deaths in the western world 1. In Europe, CVDs are the 
most frequent cause of death in men under 65 years of age and the second most common in 
women 2. Atherosclerosis is a systemic arterial disease affecting mostly the intima of large - 
and medium sized systemic arteries like the aorta, carotid, coronary and peripheral arteries 
and may lead to cardiovascular events such as acute coronary syndrome (ACS), sudden death, 
stroke and gangrene of lower extremity.
The atherosclerotic lesions tend to develop in specific areas in the vasculature with disturbed 
non-laminar flow 3. Based on the criteria by the American Heart Association Committee  on 
Vascular Lesions, later modified by Fuster et al, the atherosclerotic process can be divided 
into five pathological/clinical phases 4-6 (Figure 1).
Figure 1. Clinicopathologic correlation of asymptomatic atherosclerosis leading to 
symptomatic atherothrombosis.  Modified from Corti and Fuster 7.
Type I lesion in phase 1 is characterized by the presence of isolated groups of monocyte-
derived macrophages containing lipid droplets (foam cells), the earliest stage of 
atherosclerosis which has been recognized in 45% of infants the first 8 months of life 8, 9.
Fatty streaks, a type II lesion, are more distinctly defined with foam cells organized in layers 
with the presence of  smooth muscle cells (SMC) also containing lipid droplets, quite 
common in young children 5, 10, 11.  Type III lesions (phase 1) also include SMCs surrounded 
by extracellular connective tissue, fibrils and lipid materials. In phase 2 the lesions become 
6more advanced consisting of accumulated cellular material with more extracellular lipid 
intermixed with normal intima (type IV lesion) and dominated by an extracellular lipid core 
covered by an acquired fibrous cap (type Va lesion). Ruptured or eroded type IV or Va 
lesions (lesion type VI) are seen in phase 3 and may lead to thrombosis, usually clinically 
silent. In phase 4 lesion type VI is complicated by fixed or repetitive occlusive thrombosis 
leading to ACS including AMI, if apparent in a coronary artery. Lesion type Vb (calcific) and 
Vc  (fibrotic) is categorized in phase 5 of atherosclerosis and may cause angina pectoris.  
The progression of atherosclerosis in humans is partly dependent on genetic susceptibility and 
the presence of risk factors like smoking, hypertension, dyslipidemia (especially elevated 
LDL cholesterol), diabetes mellitus and obesity 12. However, our knowledge of the links 
between risk factors and pathobiology is incomplete. The listed risk factors for 
atherothrombosis are not always present in individuals suffering acute myocardial infarction 
(AMI) or stroke. Clinical investigations, animal studies, population studies and cell-culture 
experiments have shown that inflammatory processes are deeply involved in all phases of 
atherosclerosis and represent a final common pathway for transducing the effects of risk 
factors into changes in the arterial wall 2.  Although oxidized LDL cholesterol is a key 
component in the atherosclerotic process, the immune response locally in the arterial wall and 
systemically might be more important for the progression of atherosclerosis in some 
individuals 13. These considerations are supported by animal studies indicating that 
immunization with oxidized LDL might suppress atherosclerosis 14.
4.1.2 The atherosclerotic process 
Regardless of the cause of atherosclerosis, the endothelium plays a central role in all phases of 
the atherosclerotic process and may be exposed to various injuries like modified LDL 
cholesterol, free radicals from smoking, hypertension, diabetes mellitus and disturbed flow, 
resulting in dysfunctional endothelium assessed clinically by impaired nitric oxide-mediated 
vasodilatation 15, 16. The dysfunctional endothelium is leaky and atherogenic lipoproteins from 
plasma are retained in the subendothelial space, modified and oxidized exerting a broad range 
of pro-atherogenic effects 17. The injured endothelium responses with expression of cellular 
adhesion molecules (CAMs) 2, 18 (Figure 2).
7Figure 2. Transmigration of leukocytes. Adapted from P. Libby 19.
Oxidized LDL cholesterol is a  key component in the activation of endothelial cells and 
macrophages whereby expression of  different CAMs on the surface of  endothelial cells take 
place, also mediated by cytokines like tumor necrosis factor D (TNFD) and interleukin 6
(IL-6) 17, 20-22.  CAMs  like    E-selectin,  P-selectin,  intercellular adhesion molecule 1 
(ICAM-1) and vascular cellular adhesion molecule 1 (VCAM-1) are all involved  in  the
rolling,  adhesion  and  extravasation  of  monocytes  and  T-lymphocytes 23-26.
HDL cholesterol may reduce adhesion and transmigration of leukocytes into the 
subendothelial space as well as inhibit LDL oxidation and promote efflux of cholesterol from 
the arterial wall 27. The recruitment of leukocytes into the arterial intima is contributed by 
chemokines like monocyte chemoattractant protein 1 (MCP-1) and interleukin 8 (IL-8) 28-30.
Monocytes entering the subendothelial space are differentiated into macrophages induced by 
macrophage colony-stimulating factor 31. In the arterial wall macrophages express scavenger 
receptors mediating uptake of oxidized LDL cholesterol and apoptotic cell fragments, and  
toll-like receptors that can bind stress proteins like human heat shock proteins as well as 
oxidized LDL cholesterol and thereby activate the cell (Figure 3) 32, 33.  Once the 
macrophages have taken up lipid derivates and become foam cells they may replicate and 
elaborate a number of cytokines, chemokines, growth factors, metalloproteinases (MMPs), 
other hydrolytic enzymes and pro-thrombotic tissue factor 15. Furthermore, apoptosis and 
necrosis of the lipid rich foam cells, endothelial cells and SMC in the atheroma may soften 
and destabilize the plaque core and thereby promote plaque rupture. In addition, both 
activated macrophages and SMC may express class II histocompatibility antigens on their cell 
8surface making them capable to present antigens to T-lymphocytes, mechanisms shown to be 
present in atherosclerosis 34. T-lymphocytes, predominantly CD4+, are highly involved in the 
atherosclerotic process at all stages and are recruited to the subendothelial space by selectins 
and MCP-1 14.  In advanced atherosclerotic lesions T-cells constitute up to 10-20% of the 
present cells, often accumulated at the rupture site and about 40% express macrophage 
markers, whereas most of the remainders are SMC with a small number of mast cells, B cells 
and dendritic cells 13, 35, 36. When the T-cells are presented for antigens like oxidized LDL 
cholesterol and heat-shock protein 60, activation of the cell occurs with increased expression 
of cytokines, cell-surface molecules and enzymes 2. In atherosclerosis, the type 1 helper T cell 
(Th1) response leads to a pro-inflammatory response with elaboration of pro-inflammatory 
mediators like interferon Ȗ, lymphotoxin, CD40 ligand (CD40L), TNFD, IL-6 and C-reactive 
protein (CRP) 2, 37.  Activation of the Th2 pathway on the other hand may promote synthesis 
of anti-inflammatory cytokines like IL-10 and dampen the inflammatory process 2.
Transforming growth factor ȕ (TGFȕ), another cytokine with anti-inflammatory properties, 
produced by endothelial cells, SMCs, macrophages, platelets and regulatory T-cells, is in 
addition to IL-10 an important  inhibitor of  T-cell mediated immunity and may inhibit the  
atherosclerotic process 2, 38.
SMCs play a central role in the formation of the fibrofatty lesion, entering the arterial intima 
from tunica media, but may also be derived from the bone marrow (Figure 3).  
Figure 3. Formation of the fibrofatty plaque. Adapted from P.Libby 19.
9They respond to a great number of signal substances including chemoattractants like platelet-
derived  growth factor that promotes migration of SMCs into the intima 19. TGFȕ may 
stimulate SMCs to produce extracellular matrix containing collagens, elastin and 
glycosaminoglycans contributing to lesion fibrosis and plaque stabilization 39. However, 
incessant atherogenic stimuli may lead to an excessive fibroproliferative response resulting in 
lumen narrowing, reduced blood flow and ischemia. Although recruitment, proliferation and 
synthetic activities of SMC are mainly beneficial in atherosclerosis, apoptosis and necrosis of 
these cells are present at plaque rupture sites and thereby probably contribute to plaque 
destabilization.
4.1.3 Plaque disruption 
During the progression of atherosclerosis the plaques may grow silently for many years until 
flow-limiting obstruction occurs with ischemia, or until sudden onset of thrombosis on a 
ruptured or eroded plaque induce more dramatic clinical events like ACS (Figure 4).  
Figure 4. Two types of plaque disruption that may lead to thrombosis. Adapted from P.Libby 
19.
Clearly, two types of atherosclerotic plaques exist. Atheromas may remain silent and stable 
throughout life without cardiovascular events, or become prone to thrombosis in response to a 
wide array of local and systemic influences that are patient specific 40. Several clinical 
observations indicate that AMI not necessarily results from high grade stenosis, but from 
lesions without flow limitation 41, 42. Inflammatory activation appears to be important, not 
only for progression of atherosclerosis, but also for developing vulnerable plaques with 
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subsequent disruption and thrombosis 18. Unstable plaques often consist of  a soft lipid-rich 
core with apoptotic SMCs and macrophages, a fragile and thin fibrous cap with inflammation 
in the cap and the plaque shoulders 43. Activated macrophages, T cells and mast cells are 
present at the sites of plaque rupture and produce a large number of inflammatory cytokines 
like interferon Ȗ and TNFD, proteases like MMPs and cystein proteases and prothrombotic 
factors like tissue factor 36, 44, 45. These factors contribute to destabilize the plaque core and 
weaken the cap 2. Eventually the fibrous cap may disrupt, leading to thrombosis mainly by 
two mechanisms (Figure 4). Cap fracture is the most common mechanism underlying ACS 
(60-70%) whereas superficial erosion of the plaque is less frequently present (25%) 46.
Plaque rupture exposes underlying pro-thrombotic material like collagen and tissue factor, to 
the circulating blood. Exposure of the subendothelial elements like collagen, microfibrils and 
laminin lead to platelet activation, platelet adhesion, mediated by von Willebrand factor and 
platelet aggregation by fibrinogen bridging the activated platelets, and thereby forming a 
platelet-rich clot.  At the same time activated platelets release a large number of substances 
like ADP, serotonin, thromboxane A2, platelet-derived growth factor, fibrinogen, P-selectin 
and CD40L contributing to enhanced platelet activation and increased inflammation. Tissue 
factor, at the lesion site, complexes with Factor VIIa resulting in thrombin generation and 
fibrin formation, stabilizing the platelet-rich clot.  
The CD40-CD40L system is a key system linking activated platelets to increased 
inflammatory response in the arterial wall 47. CD40L (CD 154) is a transmembrane protein, a 
member of the TNFD superfamily, and has been identified on stimulated  T-cells, mast cells, 
basophiles, granulocytes and platelets 47. CD 40, a cell membrane-spanning protein, is present 
on B-lymphocytes, monocytes, macrophages and endothelial cells 47, 48.  CD40L is therefore a 
central element in the activation of many types of the CD40 expressing cells and this 
interaction may result in production of several inflammatory signal molecules like interleukin 
1 ȕ (IL-1ȕ), IL-6, TNFD, IL-8 and MMPs promoting increased inflammation in the vessel 
wall 48.
Most plaque disruptions are however silent, without causing clinical events. Several factors 
both locally and systemically may influence on the faith of a plaque disruption such as plaque 
dependent thrombogenic substrates, rheology and systemic procoagulant activity, all 
influenced by inflammation, possibly balanced by antithrombotic mechanisms, endogenous or 
by specific therapeutics 4. Anyway, eventually an occluding plate-rich thrombus may develop 
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resulting in ACS that may lead to life-threatening tissue damage (AMI). In ACS, there is 
compelling evidence for the presence of numerous vulnerable and active plaques in the 
coronary arteries beyond the culprit lesion 49. Intravascular ultrasound studies have shown 
that 20-80% of the patients with ACS had multiple disrupted plaques in other areas than the 
culprit lesion which underscores the presence of widespread inflammatory activity in the 
coronary arteries 50-55.
Beyond doubt, inflammatory processes are central in all stages of atherosclerosis and 
represent a common pathway for the influence of a number of risk factors on the vascular 
wall. 
4.2  Stable angina pectoris 
4.2.1 Clinical manifestations 
Angina pectoris (AP) is a clinical syndrome and the diagnosis is based on clinical assessment, 
laboratory tests and specific cardiac investigations. In the majority of cases, the AP patients 
have a characteristic discomfort usually located in the chest near the sternum, but can also be 
felt in the epigastrium, shoulder regions, either arm to the wrist and fingers, between the 
shoulder blades or the lower jaw or teeth. Typically, the discomfort is provoked by exertion or 
emotional stress and relieved by rest and/or use of nitroglycerine. Less common is myocardial 
ischemia without symptoms (silent ischemia). Atherosclerosis in the coronary arteries is the 
most common cause of myocardial ischemia and AP, but hypertrophic or dilated 
cardiomyopathy and aortic valve stenosis may also cause similar symptoms. 
AP is caused by myocardial ischemia as a result of an imbalance between myocardial oxygen 
demand and supply. Adenosin from the ischemic myocardium appears to mediate chest pain 
through stimulation of angiotensin 1 receptor on cardiac nerve endings 56. The oxygen supply 
to the myocardium is dependent on arterial oxygen saturation and myocardial oxygen 
extraction and coronary flow determined by the luminal  area of the coronary artery and 
arteriolar tone 57. Maximal flow during exercise can usually be maintained when luminal 
diameter reduction is  40%, but reduced blood flow with subsequent myocardial ischemia 
may occur during stress with a lumen diameter reduction of  > 50% 58. However, the 
individual ischemic threshold is also influenced by factors like degree of development of 
collateral circulation and coronary vascular tone. 
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4.2.2 Diagnosis and treatment 
Evaluation of AP patients includes a careful history, physical examination and objective tests. 
Exercise electrocardiogram is frequently used as a non-invasive test for detecting myocardial 
ischemia. Other tests like perfusion scintigraphy and echocardiography with exercise or 
pharmacological stress are also used as supplementary diagnostic tools in AP patients. 
Computer tomography and magnetic resonance arteriography are non-invasive techniques that 
may give information about the likelihood for coronary artery disease, but are not 
recommended as routine clinical practice at the present time. Coronary arteriography is 
usually performed in all patients with stable AP to indentify the presence or absence of 
coronary lumen stenosis, define therapeutic options and determine prognosis.  
The treatment of AP patients includes medical treatment and myocardial revascularization 
with percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery 
(CABG) when suitable. Pharmacological treatment of stable AP includes low-dose aspirin, 
lipid lowering therapy and anti-ischemic therapy with betablocker and/or nitrates and/or 
calcium channel blockers where appropriate. After PCI with stent implantation in the 
coronary arteries additional anti-platelet therapy is given for a limited period of time to avoid 
stent thrombosis.  
4.3  Acute myocardial infarction  
4.3.1 Clinical manifestations, diagnosis and treatment 
AMI is characterized by myocardial cell death as a consequence of prolonged myocardial 
ischemia.  In acute coronary syndrome, which involves ST-elevation myocardial infarction 
(STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina pectoris, 
plaque disruption with the formation of a thrombus in a coronary artery, is the underlying 
cause of myocardial ischemia. In STEMI the infarct-related epicardial coronary artery is 
occluded more often than in NSTEMI 59.
AMI may have different presentations in individual patients, ranging from none at all to 
sudden cardiac death. Most often the symptom of AMI is characterized by persistent chest 
pain with radiation into the jaw/teeth, shoulder, arm and/or back without pain relief of 
nitroglycerin.  Associated symptoms like dyspnoea, nausea, vomiting, diaphoresis and 
sweating are often present. 
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The clinical diagnosis of AMI is based on a typical rise and gradual fall of biochemical 
markers specific for myocardial necrosis (troponin T or I, creatinin kinase MB) and either 
ischemic symptoms or ECG changes (development of Q-waves, ST-segment elevation or 
depression) or PCI 60.
In STEMI early and complete reperfusion of the occluded coronary artery is a key factor to 
minimize myocardial cell death. Revascularization therapy in STEMI includes either 
thrombolysis or PCI or the combination of both. The pharmacological long-term treatment 
after AMI consists of anti-thrombotics (aspirin and/or warfarin, clopidogrel for a limited 
period of time), lipid lowering treatment (statin), beta blocker, and when left ventricular 
dysfunction is present inhibitors of the renin-angiotensin-aldosteron system (angiotensin 
converting enzyme inhibitor, angiotensin II receptor blocker, aldosteron antagonists).
4.3.2 Pathophysiology 
The hallmark for AMI is myocardial cell death due to necrosis which triggers an 
inflammatory reaction that results in healing and formation of a scar. The net effect of the 
inflammatory response in AMI can be favourable leading to healing and restoration of 
function (physiological), or unfavourable, leading to cardiac rupture or chronic dilatation and 
heart failure (pathological) 61.
Notably, most of our knowledge about the inflammatory reaction in AMI is described in 
animal models and may differ from humans 62. Based on animal models, the healing process 
in AMI, reperfused with PCI, can be divided into three overlapping phases:
i) The inflammatory phase, the first 72 hours in AMI, is dominated by a complex and 
extensive inflammatory response that includes cytokine and chemokine induction with 
subsequent transmigration of leukocytes. Neutrophils and macrophages play an important role 
in removing dead tissue and contribute to further signalling with eventual healing of the 
infarct area.  
ii) In the proliferative phase (2-7 days after AMI start) the inflammatory signalling is 
suppressed and replacement of dead cardiomyocytes by granulation tissue is taking place. 
Fibroblasts and endothelial cells infiltrate the infarct area. Extracellular matrix proteins are 
produced by myofibroblasts and an extensive microvascular network evolves.  
iii) In the maturation phase, 7 – 21 days after AMI start, fibroblasts and vascular cells undergo 
apoptosis, a collagen-based matrix network evolves, and a matured scar is formed. The 
healing process in AMI results in profound changes in ventricular architecture and geometry 
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(ventricular remodeling) which may manifest clinically as increased ventricle size, altered 
shape of the ventricle and impaired cardiac function 62.
Studies have shown that 30-40 minutes of ischemia is sufficient to induce necrosis of 
cardiomyocytes 62. Necrotic myocytes release their intracellular contents and initate an intense 
immune response mediated by toll-like receptor mediated pathways, complement activation 
and generation of reactive oxygen species. The transcriptional nuclear factor NB activation 
along with complement activation and free radical generation, is critical in the regulation and 
expression of cytokine, chemokine and adhesion molecules in both resident and blood-derived 
cells in AMI 63. In rodent models of AMI there is a marked up-regulation of pro-inflammatory 
cytokines like IL-1ȕ, TNFD and IL-6  in the infarct area as well as in the non-infarcted 
myocardium, within the the first hours 64, 65.
Early in the hyperacute phase of AMI, cardiac mast cells degranulate and release preformed 
TNFD which probably is a key component in initiating the cytokine cascade 66. Studies have 
shown that TNFD may induce IL-6  in infiltrating mononuclear cells in the infarct area 66.
In AMI there is a loss of cardiac cells because of necrosis and apoptosis. TNFD may exert 
significant effects on host cells with the potential for apoptosis versus cell survival 67.
Furthermore, TNFD and IL-1ȕ may promote fibroblast proliferation and synthesis of 
extracellular matrix by inducing the expression of angiotensin II type 1 receptor on fibroblasts 
68.
Pro-inflammatory cytokines like IL-1ȕ, IL-6 and TNFD are also associated with the 
remodeling process in AMI and may promote changes directly in cardiac myocytes like 
apoptosis, hypertrophy, contractility disturbances and inflammatory signal transduction 69-72.
TNFD and IL-6 may attenuate myocyte contractility directly through the immediate reduction 
of systolic cytosolic calcium 73.
Transmigration of leukocytes into the infarcted area is dependent on adhesion molecules and 
chemokines like IL-8, MCP-1 and macrophage inflammatory protein-1D (MIP-1D). IL-8 
plays an important role in the recruitment of neutrophils and up-regulation of IL-8 in animal 
models with AMI has been documented 74. In addition to promote recruitment of monocytes 
and T-cells,  MCP-1 induces angiogenic effects and may promote collagen formation  75, 76.
The anti-inflammatory cytokines IL-10 and TGFȕ are important factors in 
modulating/suppressing the inflammatory response in AMI. In animal models IL-10 mRNA 
expression has been demonstrated in AMI with a peak at 96-120 hours after reperfusion 77.
IL-10 inhibits the production of IL-1ȕ, TNFD, IL-6, IL-8 and promotes synthesis of tissue 
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inhibitor of metalloproteinases 1 (TIMP-1) 77, 78.  TGFȕ is a key regulator of the healing 
process in AMI with a wide range of effects including regulation of cell proliferation, 
differentiation, apoptosis and modulating the immune response 62.  In vitro studies have 
shown that TGFȕ inhibits expression of pro-inflammatory cytokines and chemokines and 
promotes extracellular matrix deposition 62. Although the origin of fibroblasts in AMI healing 
remains unclear, TGFȕ plays a central role in myofibroblast differentiation 79.
The CD40-CD40L-system may also play a role in the inflammatory response in AMI, 
particularly by the expression of CD40L on activated platelets triggering increased production 
of pro-inflammatory cytokines by endothelial cells and monocytes/macrophages. 
4.4 Circulating inflammatory mediators in coronary heart disease 
Inflammation is present in atherosclerosis and in AMI. However, the degree of inflammatory 
responses is difficult to track and evaluate directly. No imaging techniques that can monitor 
changes of inflammation are available for clinical use and biopsies are not practical or 
suitable for this purpose. Inflammatory reactions in the vessel wall and in the infarcted area 
lead to increased production of a number of cytokines, chemokines and other signal 
substances partly released from the affected area, and also from circulating blood cells and 
other organs, especially the liver. Circulating biomarkers of inflammation measured from 
blood samples, may reflect the inflammatory process in atherosclerosis and AMI, providing 
valuable information about the extent of inflammation.  
The present work is mainly focused on evaluating the levels of the circulating soluble forms 
of selected biomarkers in stable angina pectoris and AMI. 
As described, cytokines like IL-1ȕ, IL-6, TNFD, and CD40L are all pro-inflammatory 
substances linked to the progression of atherosclerosis and cardiovascular events. 
Chemokines like IL-8, MCP-1 and MIP-1D are deeply involved in the recruitment of 
leukocytes into the injured tissue (arterial wall, infarcted area) and thereby promoting 
inflammation. Anti-inflammatory cytokines like IL-10 and TGFȕ may on the contrary 
modulate and suppress the activity of the pro-inflammatory cytokines.
CD40L
CD40L is a transmembrane protein expressed by a large number of cells like T-and B-
lymphocytes, SMCs, mast cells and platelets, the latters alone are the source of 95% of the 
circulating sCD40L 80. Interaction between sCD40L and its receptor CD40 on cells like 
16
endothelial cells and monocytes, may lead to elaboration of a large number of inflammatory 
mediators 81. Increased levels of sCD40L have been associated with future cardiovascular 
events in healthy women 82. Similarly, in patients with ACS, elevated levels of sCD40L have 
been related to increased risk of recurrent events 83-85.
IL-6 
IL-6 is a central mediator of the acute-phase response with a broad range of humoral and 
cellular immune effects 86. Up to 30% of the total circulating IL-6 originates from 
subcutaneous adipose tissue 87. Studies have shown an association between elevated levels of 
IL-6 in men without CVD and in women with existing CVD and increased risk for 
cardiovascular events 88, 89. However, limited data exist for a clear association between IL-6-
levels and CVD independent of other risk factors.
CRP 
CRP is the classic acute phase reactant produced by the liver in response to inflammatory 
stimuli like IL-6 90. In contrast to IL-6, CRP is released in larger amounts in response to 
inflammatory stimuli without diurnal variation. Clearly, CRP is, at the present time, the most 
robust inflammatory biomarker in CVD and large epidemiological studies have shown that 
elevated CRP levels predict increased risk for CVD in both healthy people and in individuals 
with CVD 91-106.
TNFD
TNFD was initially identified as products of lymphocytes and macrophages that caused lysis 
of certain cells, especially tumor cells 107. Later research has shown that TNFD is involved in 
multiple human diseases including atherosclerosis and AMI. Several studies have shown that 
increased levels of circulating TNFD predicts coronary heart disease and other CVD in 
humans 108-110.
MCP-1
Chemokines like MCP-1 is involved in the recruitment of monocytes into the arterial wall as 
well as into the infarcted area in AMI. In addition, MCP-1 may induce production of tissue 
factor in the arterial wall 111. Limited data exist, but studies have shown an association 
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between plasma levels of MCP-1 and traditional risk factors for atherosclerosis and clinical 
outcomes in patients with ACS 112, 113.
IL-8 
IL-8  appears to be  the primary chemokine responsible for the activation and recruitment of 
cytotoxic neutrophils into the ischemic myocardium and has been shown to be up regulated 
by oxidized LDL cholesterol in atherosclerosis 114, 115. Elevated levels of IL-8 after PCI in 
patients with stable AP, have been associated with more cardiac events and restenosis 116.
IL-10 
IL-10,  an anti-inflammatory cytokine, tends to modulate the inflammatory cellular signalling 
pathways in atherosclerosis and AMI 15, 34, 39. Clinical studies on circulating levels of  IL-10 
during stable coronary heart disease and ACS are inconclusive 117. However, increased levels 
of circulating IL-10 have been associated with reduced risk for recurrent cardiovascular 
events in patients with ACS 118, 119.
TGFȕ
TGFȕ has a broad range of biological effects including the control of cellular proliferation and 
differentiation, regulation of tissue repair and extracellular matrix accumulation and 
modulation of immune and inflammatory responses. Low levels of  TGFȕ have been 
associated with advanced atherosclerosis and are likely to lead to an exaggerated 
inflammatory response 120-122.
4.5 Long-term anti-platelet therapy in coronary heart disease 
Platelets are essential in the development of a thrombus on a disrupted plaque that may lead to 
a clinical event. In addition, platelets harbour a large number of signal molecules that may 
increase the inflammatory response in the arterial wall.
Acetylsalicylic acid or aspirin is widely used in patients with atherosclerotic disease including 
coronary heart disease. Aspirin binds to and then irreversibly acetylate the catalytic site of 
cyclooxygenase in platelets which is required for the metabolism of arachidonic acid to 
prostaglandin H2 (PGH2) 123. PGH2 in platelets is processed to thromboxane A2 which is a 
potent activator of platelets and promote platelet aggregation. Aspirin, in doses of 75 to 325 
mg daily, is well documented to reduce the risk for cardiovascular events in a broad range of 
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patients with atherosclerotic diseases 124. In addition to its antithrombotic effects, aspirin 
possesses anti-inflammatory properties  that  may reduce vascular inflammation 125.
Clopidogrel is another anti-platelet agent, acting by blocking the binding of ADP to a specific 
platelet receptor P2Y12 and thereby inhibit adenyl cyclase activity, resulting in reduced 
activation of GP IIb/IIIa receptors and platelet aggregation 126. Large clinical trials have 
shown that clopidogrel in addition to aspirin for a limited period of time reduces recurrent 
clinical events in patients with ACS as well as after PCI 127, 128. However, limited data exist 
about the influence of clopidogrel on inflammation in patients with coronary heart disease. 
4.6 Treatment of acute myocardial infarction with intracoronary injection 
       of autologous mononuclear bone marrow cells.       
In acute myocardial infarction there is a net loss of cardiomyocytes due to necrosis and 
apoptosis which may lead to heart failure and death.  Although myocyte proliferation occurs 
in human hearts, this regeneration is obviously inadequate after AMI 129, 130. Both animal and 
human studies have shown that bone marrow cells may home to the myocardium, but the role 
and function of these cells in cardiac repair are not clarified 131-134. Animal studies have 
shown that intramyocardial injection of cell types like hematopoietic stem cells from the bone 
marrow, may improve left ventricular function in AMI, and even transdifferentiation of 
hematopoietic stem cells into cardiomyocytes has been reported in mice 135. Therefore, 
myocardial cell-based repair has been proposed as a therapeutic option in patients with 
myocardial damage. Until 2003 only a few safety studies with intracoronary injection of bone 
marrow cells in patients with AMI had been performed, and no adverse effects of this 
treatment could be demonstrated 136, 137. Even a possible beneficial effect on left ventricular 
function was reported, but larger studies were clearly needed 136, 137. In addition, several 
issues were at that time not clarified like underlying mechanisms for potential beneficial 
effects of stem cell transplantation, optimal cell type and number, timing after AMI, and 
delivery methods. The optimal time for delivery of mBMCs in AMI is dependent on several 
factors like the presence of homing signals and the inflammatory environment 138. A marked 
pro-inflammatory environment with rise in reactive oxygen species might be deleterious for 
the injected cells. Furthermore, intracoronary injection of mBMCs as well as bone marrow 
aspiration may also influence on the inflammatory environment affecting both the 
myocardium and coronary arteries.
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5  Aims of the study 
Inflammation is deeply involved in all phases of atherosclerosis and in AMI. The main 
purpose of the present work was to investigate the influence of specific treatment modalities 
on inflammatory responses in patients with stable coronary heart disease or AMI. 
More precisely, we wanted to assess: 
¾ … the influence of aspirin on circulating biomarkers of inflammation in patients             
     recovered from AMI. (Paper I) 
¾ … the effects of clopidogrel as compared to aspirin on selected circulating
           inflammatory markers in patients with stable angiographically verified CHD.
           (Paper II)
¾ … the profile of circulating inflammatory mediators in patients with AMI as compared  
           to patients with stable angina pectoris, all treated with PCI and stent implantation.
           (Paper III) 
¾ … the effect of intracoronary injection of autologous mBMCs on systolic left     
           ventricular function in patients with AMI. (Paper IV) 
¾ … the influence of  intracoronary injection of autologous mBMCs on selected     
circulating inflammatory mediators in patients with AMI. (Paper V)
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6  Material and methods 
6.1 Study subjects and design 
In Paper I, we studied  patients participating in the Warfarin Aspirin Re-Infarction Study
(WARIS II) 139. A total of 310 patients, recovered from AMI, both gender, age about 60 
years, 30% smokers, LVEF 45%, 70% on statin treatment, recruited from Ullevål University 
Hospital, Oslo, Norway were randomly included in the present substudy: 102 patients on 
warfarin alone with target International Normalized Ratio (INR) 2.8-4.2, 107 patients on 
aspirin 160 mg o.d. alone and 101 patients on the combination of aspirin 75 mg o.d. and 
warfarin with target INR 2.0-2.5.
Study medication was started during their hospital stay and mean follow-up time was 4 years. 
Blood samples were collected 3 months after the AMI for determination of thromboxane B2,
TNFD, IL-6, IL-10 and CRP. In 210 of the 310 study subjects, while still alive and adhering 
to the randomized treatment, fasting blood samples were also drawn 4 years after the AMI.
During the follow-up period, while still being on the randomized treatment, relevant clinical  
events were recorded. The study protocol was approved by the Regional Ethics Committee 
and all patients gave written informed consent to participate. 
      In paper II, we studied a random subgroup of patients from the ASpirin non-responsiveness and 
Clopidogrel clinical Endpoint Trial (ASCET) which is a prospective randomized study 
investigating aspirin non responsiveness in relation to clinical events 140. A total of 206 patients, 
age 61 years, 20% female, 50% with previous AMI, 20% current smokers and 20% with known 
diabetes mellitus type II were included. All patients  had stable coronary heart disease verified with 
coronary angiography, and were randomized to either clopidogrel (Plavix® Sanofi- Synthelabo, 
Bristol-Myers Squibb, Paris, France) 75 mg daily (n=101) or aspirin (Albyl-E®, Nycomed, Oslo, 
Norway) 160 mg daily (n=105). The participants were all taking aspirin 160 mg daily for at least 7 
days before randomization and continued all other medication according to general guidelines. In 
accordance with current guidelines 98% were on statin therapy. Medication use was similar 
between the groups, also after 1 year. Fasting blood samples were drawn at randomization and after 
1 month and 1 year for determination of CRP, TNFD, IL-6, MCP-1, CD40L, P-selectin, IL-10 and 
TGFE. The study protocol was approved by the Regional Ethics Committee and all patients gave 
written informed consent to participate. 
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In paper III, we investigated thirty men and women, age 62 years, with STEMI (n=20) or 
stable angina pectoris (n=10), admitted to Ullevål University Hospital, Oslo, Norway. All 
were treated successfully with PCI in a central coronary artery obtaining normal blood flow. 
Patients with previous transmural infarction, cardiogenic shock or considerable co-morbidity 
(i.e. short life expectancy because of malignancy, stroke, inflammatory diseases, 
endocrinological disturbances and lung disorders) were not enrolled. The included patients 
were treated in accordance with current guidelines. Blood samples were collected by standard 
venipuncture immediately before PCI, only in the AP group, and after 3 and 12 hours, 1, 3, 5, 
7 and 14 days in both groups for determination of TNFD, IL-6, CRP, MCP-1, IL-10, TGFE,
sCD40L and IL-8. The study protocol was approved by the Regional Ethics Committee and 
all patients gave written informed consent to participate. 
In papers IV and V, we included 100 patients, both gender, age 57 years, at Ullevål University 
Hospital and Rikshospitalet University Hospital between September 11, 2003 and May 4, 
2005. They all had anterior wall ST-elevation myocardial infarction within 2 – 12 hours from 
onset of symptoms to PCI, successful PCI with stent on left anterior descending artery (LAD), 
culprit lesion proximal to the second diagonal branch, t3 hypokinetic left ventricle segments 
assessed by echocardiography and creatine kinase MB >3 times upper reference value. 
Patients with previous Q-wave myocardial infarction, cardiogenic shock, severe co-morbidity 
or other conditions which interfered with patient ability to comply with the protocol were 
excluded. All patients received medication according to current guidelines. The day of acute 
PCI was defined as day zero, and at day three to five, patients were randomized 1:1 to either 
autologous mBMC or control groups. The mBMC transplantation was performed 6 days 
(median) after the AMI. 
In Paper IV, systolic left ventricular function was assessed by single-photon emission 
computed tomography (SPECT), echocardiography and MRI. Baseline SPECT and 
echocardiography were performed before cell treatment, and MRI recordings were obtained 
2-3 weeks after the myocardial infarction. After six months, SPECT, echocardiography and 
MRI were repeated.  
In Paper V, blood samples were obtained by standard venipuncture between 8 and 9 a.m. after 
a 12-hours fast the day before stem cell transplantation (baseline) (Day-1) in the mBMC 
group and 1 day (Day 1), 3 days (Day 3), 2-3 weeks and 3 months  after stem cell 
transplantation (Day 0) and at corresponding time points in the control group for 
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determination of circulating levels of TNF D, IL-6, CRP, IL-8, MCP-1, sCD40L, IL-10, 
TGFE and mRNA expression in whole blood of IL-1E, TNFD, IL-8 and MIP-1D.
6.2 Stem cell injection 
The mBMC group was aspirated for 50 ml of bone marrow from the iliac crest in local 
anesthesia 4-7 days (baseline) after the acute percutaneous coronary intervention. The bone 
marrow was mixed with 10.000 IU heparin and centrifugated on a Ficoll density gradient 
(Axis-Shield, Oslo, Norway) for isolation of mBMC, washed, and resuspended in heparin-
plasma (heparin 1000 IU/ml). The next day, a median of 6 days (interquartile range 5 to 6) 
after AMI (Day 0), 10 ml of the mBMC suspension containing a median number of 68 x 106
mononuclear cells (0.7 x 106 CD34+ cells) was injected in the infarct related coronary artery 
(Left Anterior Descending artery). After administration of heparin 100 IU/kg body weight 
intravenously, a 0.5 mm oversized over-the-wire balloon catheter was advanced to the 
proximal part of the stent on the culprit lesion and inflated with very low pressures (< 2 bar) 
for 90 seconds obtaining no-flow. At the same time, one third of the stem cell suspension, 
followed by 2 ml heparinized saline, was injected distally, followed by deflation of the 
balloon and re-flow for 5 minutes between a total of 3 injections (10 ml). The control group 
was not aspirated for bone marrow and did not go through any further coronary intervention 
with intracoronary injections and administration of heparin.  
6.3 Evaluation of left ventricular function 
Myocardial scintigraphy 
Perfusion imaging was performed as ECG-gated SPECT after injection of 99mTc-
tetrofosmine (Myoview™ , Amersham Health, UK). The injected dose was 500MBq in 
baseline studies, and 250-300MBq (weight-adjusted) in 6 month studies. An Exeleris (GE 
Medical Systems) processing station, with the 4D-MSPECT™ software, was used for 
processing of all recordings and assessment of left ventricular volumes and infarct size 
(proportion perfusion defect). The method is described in more detail in Paper IV. 
Echocardiography
Vivid 7 scanner (GE Vingmed Ultrasound, Horten, Norway) was used for echocardiography 
recordings. Three apical views with three consecutive cineloops were recorded for analysis on 
a separate work station by a single physician. EchoPAC PC software (GE Vingmed 
Ultrasound) was used and left ventricular volumes were computed using the modified 
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Simpson`s rule according to current guidelines. The method is described in more detail in 
Paper IV. 
Magnetic resonance imaging 
MRI was performed using a 1.5 tesla Siemens scanner Magnetom Vision Plus (Erlangen, 
Germany) for the first 18 months of the study, and Magnetom Sonata, Siemens (Erlangen, 
Germany), for the last 10 months. Breath-hold cine images in two-chamber, four-chamber and 
short axis views were acquired. Approximately 10 – 20 minutes after intravenous injection of 
0.2 mmol/kg gadopentetate dimeglumine (Magnevist, Schering, Berlin, Germany), late 
contrast enhancement images were obtained, first in two-chamber and four-chamber views, 
and then with multiple short axis slices covering the entire left ventricle with a slice thickness 
of 7 mm and an interslice gap of 3 mm. For each slice the total area of the left ventricular wall 
and the area of late enhancement were manually drawn, and the areas were summed for 
calculation of total left ventricular wall volume and total late enhancement volume . Infarct 
size is presented as total late enhancement volume and as a proportion ((total late 
enhancement volume / total left ventricular wall volume) x 100 %). The method is described 
in more detail in Paper IV. 
All evaluations were performed without knowledge of the patients treatment given in the 
randomized trial. 
6.4 Laboratory analyses 
Circulating levels of the inflammatory mediators in serum and plasma were measured by 
commercially available enzyme immunoassays, described in more detail in the papers.
Whole blood for mRNA analysis was collected in PAXgene Blood RNA Tubes (PreAnalytiX 
GmbH, Hombrechtikon, Switzerland) by standard venipuncture and stored at -70˚C after 
initially kept at room temperature for at least 2 hours. RNA was extracted using PAXgene 
Blood RNA Kit and reversely transcribed. Gene expression of interleukin 1E, TNFD, IL-8 and 
macrophage inflammatory protein-1D  was assessed by use of Real-Time reverse transcription 
polymerase chain reaction. Results are presented relative to the gene expression of 
glyceraldehyde-3-phosphate dehydrogenase (house keeping gene). The method is described in 
detail in paper V. 
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6.5 Statistics 
Variables are expressed as proportions, means ±SD or medians with 25, 75 percentiles when 
skewed data. In Paper I, II, III and V the levels of inflammatory mediators were not normally 
distributed and non-parametric statistical methods were used. Differences between groups 
were assessed by the Mann-Whitney test or the two-sample t-test when appropriate. Wilcoxon 
test was used to assess within group changes from baseline to later time points. In Paper V, 
the significance of differences in changes from baseline between groups was tested by 
analysis of co-variance on log-transformed data. SPSS software package for Windows and 
Epi Info for Windows were used for data analyses. 
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7  Summary of results 
7.1 Paper I 
We assessed the influence of aspirin on selected inflammatory markers in patients 3 months 
after AMI and the relation to relevant clinical events after 4 years. We also evaluated the 
stability of the inflammatory markers during long term aspirin treatment for 4 years.  
We studied patients participating in the Warfarin Aspirin Re-Infarction Study                
(WARIS II), which compared the efficacy and safety of warfarin, aspirin and the two 
combined  as secondary prophylaxis after an AMI 139. In the present substudy a total of 310 
patients, recruited from Ullevål University Hospital, Oslo, Norway were randomly included: 
102 patients on warfarin alone, 107 patients on aspirin 160 mg o.d. alone and 101 patients on 
the combination of aspirin 75 mg o.d. and warfarin.  Statistically significantly lower levels of 
CRP in patients treated with aspirin 160 mg o.d. as compared to the warfarin alone group 
could be demonstrated 3 months after AMI. The same profile appeared in the levels of TNFD
and IL-6, but the differences were of borderline significance. In all treatment groups 
significantly lower levels of CRP and TNFD were found after 4 years (n = 210). Noteworthy, 
however, in general, the differences between the treatment groups were maintained.  The 
difference in IL-6 between the aspirin 160 mg o.d. alone group and the warfarin alone group 
attained statistical significance after 4 years, and also in the combined group the levels were 
significantly reduced compared to the warfarin alone group.
Taken together, reduced levels of pro-inflammatory markers in patients treated with aspirin 
160 mg o.d. compared to warfarin for up to 4 years after an acute myocardial infarction were 
demonstrated. These findings were, however, not reflected in the incidence of clinical end-
points after 4 years.
7.2 Paper II 
While aspirin is known to reduce several pro-inflammatory markers in patients with coronary heart 
disease (CHD), limited data exist regarding the influence of clopidogrel. The aim of this study was 
to assess the influence of clopidogrel as compared to aspirin on selected circulating inflammatory 
markers in patients with stable angiographically verified CHD. Patients on treatment with aspirin 
160 mg o.d. for at least 7 days were randomized to either continuing aspirin 160 mg o.d. (n=105) or 
clopidogrel 75 mg o.d. (n=101) and followed for 1 year. There were no differences in any of the 
measured inflammatory variables including changes from baseline to 1 month and 1 year, between 
the groups. In the aspirin group we found significantly lower levels of TNFD and MCP-1 after 1 
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year. Likewise, in the clopidogrel group the level of TNFD was significantly reduced after 1 year. 
The present results indicate similar anti-inflammatory effects of the two drugs in patients with
CHD. 
7.3 Paper III 
We investigated the profile of selected circulating inflammatory markers after PCI in patients 
with AMI or stable angina pectoris (AP). Twenty patients with AMI and 10 patients with 
stable AP were enrolled (age 60 years, both sexes, without previous myocardial infarction), 
all treated with PCI of a central coronary artery. Blood samples were drawn immediately 
before PCI, only in the AP group, and after 3 and 12 hours, days 1, 3, 5, 7 and 14 in both 
groups. The median levels of IL-6 increased in both groups to time point 12 hours with a peak 
on day 1, but were significantly higher in the AMI group compared to the AP group at time 
points 3 and 12 hours, and also at days 1 and 3. A similar profile could be demonstrated for 
CRP with significantly higher levels in the AMI group at days 1, 3 and 5 compared to the AP 
group. A slightly different pattern was shown for IL-10 with significantly higher levels in the 
AMI group at 3 and 12 hours, days 1 and 14 compared to the AP group.
Thus, patients with AMI treated with PCI experienced a marked short term increase in 
circulating levels of pro-inflammatory mediators as well as of IL-10 compared to similarly 
treated patients with stable angina pectoris. In addition, the PCI procedure per se also   
induced an increase in IL-6 levels in patients with stable angina pectoris. 
7.4 Paper IV 
We examined the effects of intracoronary injection of autologous mBMC on left ventricular 
function in AMI. One hundred patients with acute ST-elevation anterior wall myocardial 
infarction treated with percutaneous coronary intervention were assigned to intracoronary 
injection of autologous mononuclear bone marrow cells (mBMC) (n = 50) or control group   
(n = 50) (ASTAMI trial). End-points were changes in left ventricular ejection fraction 
(LVEF), end-diastolic volume and infarct size assessed by ECG-gated single-photon emission 
computed tomography (SPECT), echocardiography and MRI from baseline to 6 months after 
the infarction. In both groups a significant improvement in LVEF (SPECT) from baseline to 6 
months could be demonstrated, but without between group differences.
SPECT, echocardiography and MRI did not show any effects on global left ventricular 
function by intracoronary injection of autologous mBMC after 6 months. 
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7.5 Paper V 
We investigated the influence of intracoronary injection of mBMC on the pattern of 
inflammatory biomarkers in patients with AMI. AMI patients in the ASTAMI trial (n=100) 
treated with PCI were randomized to intracoronary injections of autologous mBMC (n=50) or 
control (n=50). Fasting blood samples were drawn the day before stem cell transplantation 
(baseline, 4-5 days after AMI) and at day 1 and 3, 2-3 weeks and 3 months after the 
transplantation for determination of circulating levels of inflammatory markers and mRNA 
levels in whole blood samples. From baseline to Day 1, the levels of IL-6 and the expression 
of TNFD mRNA increased significantly in the mBMC group compared to the control group. 
The decrease of IL-6 levels from baseline to 2-3 weeks in the mBMC group was less 
pronounced than in the controls (p<0.05), as was also the decrease in  CRP levels from 
baseline to Day 1 and Day 3 in the mBMC group (p<0.05 for both). However, from baseline 
to 3 months the circulating levels of TNFD and MCP-1 increased less in the mBMC group 
(p<0.05 for both).
Intracoronary injection of mBMC in patients with AMI induces a marked short term pro-
inflammatory response, but a slightly reduced inflammatory pattern after 3 months. The 
results may have implications for the delivery method and timing of stem cell transplantation 
in AMI. 
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8  Discussion 
8.1 Methodological considerations 
8.1.1 Study subjects and methods 
In the present work, all the investigated patients had coronary heart disease in various stages. 
In Paper II, only subjects with stable angiographically verified coronary heart disease were 
included, whereas in paper I individuals recovered from AMI were enrolled. In paper III, 
patients with stable coronary heart disease were compared to subjects with AMI, both groups 
treated with PCI and stent implantation. In Papers IV and V only patients with AMI were 
included.
The influence of specific interventions on the inflammatory response is probably different in 
patients with stable coronary heart disease from those with AMI, which should be considered 
when evaluating the levels of circulating inflammatory mediators. In addition, the circulating 
levels of the selected inflammatory markers may not necessarily fully reflect the 
inflammatory process locally in the arterial wall and the myocardium.  
The levels of soluble biomarkers were measured by commercially available enzyme 
immunoassays kits with satisfactorily inter-assay coefficients of variation below 11%.
Several of the selected biomarkers have diurnal variation, and therefore blood samples were 
collected by standard venipuncture between 8 and 9 a.m. after 12-hours fast and before intake 
of medication, except for samples taken at 3 and 12 hours interval (Paper III).
In Paper V, the levels of mRNA were determined in whole blood reflecting gene expression 
of the selected biomarkers in circulating leukocytes and not in the myocardium and the vessel 
wall which could differ. 
8.2 General discussion 
8.2.1 Anti-inflammatory therapies in coronary heart disease 
      In Paper I we demonstrated significantly reduced levels of CRP in patients on aspirin 160 mg   
      daily compared to patients on warfarin alone 3 months post AMI. A similar difference of borderline  
      significance was observed for TNFD. In all treatment groups significantly lower levels of CRP  
and TNFD were found after 4 years, and the levels of IL-6 were significantly lower in the aspirin
alone group compared to the warfarin group as well as between the combined group and the 
warfarin group. Warfarin has not been shown to exert any anti-inflammatory properties and  
served as a control in the present study.
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Aspirin
It is now compelling evidence for anti-inflammatory effects of aspirin in patients with coronary 
heart disease. Our findings is in accordance with other studies that have shown reduced levels of 
pro-inflammatory biomarkers after treatment with aspirin  96, 141.
The reduced inflammatory activity during aspirin treatment is probably mediated by reduced 
phosphorylation of the inhibitor of nuclear factor NB and thereby inhibition of this 
transcription factor activation which is of crucial importance in inflammatory regulation 125,
142. Although animal studies have shown that aspirin reduces atherosclerosis, the clinical 
benefit of reduced inflammatory activity vs inhibition of platelet aggregation by aspirin in 
humans with coronary heart disease remains unknown 143. The lack of influence of aspirin on 
the clinical end-points in the WARIS-II trial is further discussed in para 8.2.2 (p. 30). 
In Paper II we wanted to examine the anti-inflammatory effects of clopidogrel 75 mg o.d. as 
compared to aspirin 160 mg o.d. in patients with coronary heart disease. We did not find
any between group differences in circulating markers of inflammation after 1 year treatment 
with clopidogrel 75 mg o.d. compared to aspirin 160 mg o.d., but in both groups lower levels 
of TNFD were obtained indicating similar anti-inflammatory effects.  
Clopidogrel
The mechanism behind an anti-inflammatory effect of clopidogrel is different from that of 
aspirin. Clopidogrel inhibits binding of ADP to the specific purinergic receptor P2Y12 and 
thereby decreases the activation of platelets, which seems to result in reduced expression of 
CD40L and P-selectin and thereby less inflammatory activity 47, 144. It has been shown that 
most of the effects of CD40L is confined to the membrane-bound fraction, and circulating 
levels may therefore not reflect the total physiologically effective expression of CD40L and 
P-selectin 144. In the present study the circulating levels of sCD40L and P-selectin did not 
differ between the two treatment groups. However, these findings do not exclude differences 
between the two drugs concerning the membrane-bound fraction of CD40L and P-selectin. 
Beyond doubt, an anti-inflammatory effect of clopidogrel in patients with coronary heart 
disease is present, but the clinical effect of this anti-inflammatory action in terms of reduced 
cardiovascular events is not clarified. 
Statins
In papers I and II we observed reduced circulating levels of several inflammatory markers 
during the observation time, irrespective of the study treatment. This may be partly explained 
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by other therapies with impact on the inflammatory responses. The majority of the patients 
were on statin treatment which has been shown to reduce inflammation 102, 145-148. The clinical 
benefit of statin therapy has traditionally been linked to the reduction of apoB- and apoE-
containing lipoproteins, LDL in particular, but also VLDL and intermediate-density 
lipoprotein 149. A large number of studies have shown that statins reduce myocardial 
infarction, stroke, and cardiovascular and total mortality rates in both primary and secondary 
prevention trials 150. However, the impact of the non-lipid-decreasing (pleiotropic) effects of 
statins including the anti-inflammatory properties on the clinical benefit, is not clarified.
Inhibitors of the renin-angiotensin system 
A minor part of the patients in papers I and II were treated with inhibitors of the renin-
angiotensin system (angiotensin converting enzyme inhibitors or angiotensin II receptor 
blockers). Angiotensin II promotes the activation of NF-NB, LDL oxidation and endothelial 
dysfunction 151-153. Inhibitors of the renin-angiotensin system have been shown to reduce CRP 
and pro-inflammatory cytokines 154-156. Usage of the inhibitors of the renin-angiotensin 
system may lead to reduced inflammatory activity over time which could have influenced on 
the levels of inflammatory mediators in papers I, II and V.
8.2.2 Inflammatory signal substances and atherosclerosis – the chicken or the egg? 
Atherosclerosis is, no doubt, an inflammatory disease, but whether inflammation is causal or 
casual remains unknown. Inflammatory signal substances like IL-6, TNFD, MCP-1 and 
CD40L are all deeply involved in the inflammatory process in the arterial wall as described in 
the general introduction. Even CRP, mostly produced in the liver, has been shown to exert 
direct pro-inflammatory effects in the arterial wall like downregulation of endothelial nitric 
oxide synthase, increased synthesis of endothelin-1 and IL-6 by endothelial cells, and also 
increased expression of vascular cell adhesion molecules and MCP-1 157-161.  Furthermore, 
CRP itself is a potent chemoattractant for monocytes, facilitates uptake of LDL cholesterol by 
macrophages, contribute to complement activation and stimulates SMCs migration, 
proliferation and reactive oxygen species production 162-165.
Large, prospective studies have shown that individuals with elevated levels of circulating 
biomarkers are at increased risk of cardiovascular events 82, 93-99, 101, 105, 145, 166-168. Clinical 
studies have also shown that patients in the highest CRP quartile obtain greater reduction in 
cardiovascular events with statin treatment than those in the lowest CRP quartile 102, 145.
However, there are mixed results regarding the impact of reducing the circulating 
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inflammatory markers on cardiovascular events. In paper I, (The WARIS II population) no 
differences were found in the 3 months levels of CRP and TNFD between those having an 
event after 4 month compared to those without. When dividing the variables in quartiles for 
relation to future events, no associations could be found for CRP and TNFD. As discussed in 
paper I, the lack of association between the levels of inflammatory markers and clinical end-
points could be related to superior antithrombotic effects of warfarin over aspirin in the 
WARIS-II trial. In accordance with our findings it has been shown that CRP levels measured 
at admission to hospital in patients with unstable angina pectoris did not predict risk for 
recurrent cardiac events the next 12 months 169. Furthermore, in a study including patients 
hospitalized with chest pain, no association of serum levels of CRP, IL-6 or TNFD with 
atherosclerotic burden or major cardiovascular events at 6 months was detected, when 
adjusted for traditional risk factors 170.
It is well documented that statins reduce the levels of several circulating inflammatory 
markers including CRP, TNFD, IL-6 and serum amyloid A 146, 147, 171-177.
However, the direct effects of reduced inflammatory activity per se on clinical cardiovascular 
events are difficult to interpret because of the close pathophysiological interrelationship of 
inflammation with traditional risk factors and genetic susceptibility. There is evidence for 
association between circulating inflammatory markers and risk factors like smoking, exercise, 
abdominal obesity and blood pressure 178.  Aspirin, clopidogrel and statin have all been shown 
to reduce the risk for cardiovascular events in patients with coronary heart disease, but at the 
present time, the clinical benefit of the reduced levels of inflammatory markers alone remains 
unknown.  The ultimate test for causality for inflammatory markers would be through 
randomized trials with long-term selective reduction of inflammatory signal substances 179.
8.2.3 Inflammation in acute myocardial infarction – is it good or bad? 
Cardiac repair after AMI is a highly complex process, involving inflammatory components, 
extracellular matrix remodeling, release of multiple neurohormonal stimuli and adaptive 
responses of cardiac myocytes themselves. One specific cytokine may exert a wide range of 
biological effects on various cell types and similar cytokines exert similar and overlapping 
actions on the same cells. At the same time, the balance between the pro- and anti-
inflammatory substances is crucial for the net result. 
Characteristic features of the inflammatory signal substances are their functional pleiotropy 
and redundancy. Induction and release of the pro-inflammatory cytokines like TNFD, IL-1ȕ
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and IL-6 are always present in experimental models of AMI. In Paper III we found an 
increase of the circulating levels of TNFD, IL-6, CRP and IL-10 in the acute phase of AMI in 
patients treated with PCI. Most of previous knowledge about inflammatory responses in AMI 
is based on experimental models with somewhat conflicting results underscoring the 
complexity of the inflammatory signalling in AMI. 
Animal models have shown that TNFD deficient mice undergoing infarction exhibit decreased 
chemokine and adhesion molecule expression and thereby reduced inflammatory response 
resulting in reduced infarct size 180. However, studies in mice lacking TNF receptors  
(TNFR1/TNFR2 double receptor knockout mice)  showed significantly higher infarct size  
and increased myocyte apoptosis compared to wild-type mice 181. On the contrary, another 
study using treatment with sTNFR1 expression plasmid DNA that reduced TNFD activity in 
the myocardium demonstrated inhibition of cardiomyocyte apoptosis 182. These findings 
illustrate the pleieotropic effects of TNFD which under certain circumstances may induce 
apoptosis, but could also promote cell survival. Furthermore, in vitro experiments have shown 
that TNFD is capable to induce IL-6 expression in canine mononuclear cells, and IL-6 has 
been shown to mediate ligand-specific adhesion of neutrophils to cardiac myocytes which 
may induce cytotoxic effects 183. However, in a mice model with AMI, reduced expression of 
IL-6 did not affect infarct size, left ventricular function or post-infarction remodelling 184.  In 
fact, IL-6 null mice have demonstrated delayed cutaneous wound healing, suggesting a 
significant role for IL-6 in tissue repair 185. IL-6 is also involved in inducing CRP production 
by the liver. In paper III we found a peak of IL-6 in the AMI group 1 day after PCI and the 
highest concentration of CRP was somewhat later, 3 days after PCI. Experimental studies 
have shown that the CRP response not only reflect tissue damage, but may also contribute to 
the severity of ischemic myocardial injury 186.  In humans, attempts to reduce the 
inflammatory response in AMI like the methylprednisolon trial and the phase II anti-CD18 
study have been disappointing 187, 188.
The inflammatory mediators are necessary as regulators of cardiac repair in AMI, but they 
may also mediate unfavourable effects affecting also the non-infarcted myocardium. Clearly a 
more complete understanding of the specific molecular steps in humans with AMI is needed 
before specific anti-inflammatory treatment, without interfering with healing and cardiac 
repair, can be initiated. 
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8.2.4  Intracoronary injection of mBMC in acute myocardial infarction - the effects on left
         ventricular function and the role of inflammation. 
The effects on left ventricular function 
Although cardiomyocyte replication and myocardial regeneration do occur in human hearts, 
clearly, it is insufficient to repair the injury in AMI 129. Substantial loss of cardiomyocytes 
leading to pathological left ventricular remodeling and heart failure may be seen in up to one 
third of patients with STEMI despite revascularization treatment 189.  Experimental studies 
have shown that progenitor cells from the bone marrow may improve cardiac function in AMI  
Therefore, cellular transplantation with autologous stem cells from bone marrow has been 
suggested to improve cardiac function in patients with AMI treated with PCI. Several smaller 
early-phase studies have shown the feasibility and safety of intracoronary injection of bone 
marrow cells in patients with AMI, and also a possible improvement in cardiac function has 
been reported 136, 137. Therefore, larger randomized clinical trials were started with enough 
power to elucidate the effects of intracoronary injection of mBMC on left ventricular 
function. The BOOST study (Bone Marrow Transfer to Enhance ST-elevation Infarct 
Regeneration) included 60 patients with STEMI 190. Half of the patients were randomized to 
receive intracoronary injection of autologous mBMC and the other half to the control group. 
After 6 months an improvement in LVEF (MRI) in the BMC group was detected from 50% 
(baseline) to 56.7% (6 months) compared to the control group where a surprisingly low 
increase from 51.3% to 52.0% in LVEF was observed. At 18 months follow-up, the between 
group differences in change of LVEF from baseline was not present 191.  Another study, that 
was double-blinded, randomized and placebo controlled, included 67 patients with STEMI 
(33 of the patients received intracoronary injection of mBMC) and did not show any 
improvement in LVEF (MRI) at 4 months follow-up in favour of the mBMC group 192.
LVEF at baseline was 46.9%  in controls and 48.5% in mBMC group, and increased after 4 
months to 49.1% and 51.8%, respectively (p=0.36 for treatment effect). A similar result was 
obtained by another randomized and controlled study from Prague that included 27 patients 
with large anterior wall AMI, whereof 17 patients received intracoronary injection of 
autologous mBMC 9 days after the acute PCI 193. The study was prematurely terminated 
because of 2 deaths in the mBMC group. An improvement in LVEF (echocardiography) from 
baseline (39% in both groups) to 4 months could be detected in both groups (47% in controls 
and 45% in the mBMC group), but without any between group differences. These findings are 
in accordance with the present ASTAMI study (paper IV) that also showed an increase of 
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LVEF (SPECT) from baseline (42.6% in controls vs 41.3% in mBMC group) to 6 months 
(49.3% in both groups), but without differences between the groups. So far, REPAIR-AMI, is 
the largest clinical trial that has been performed 194. A total of 204 patients with STEMI were 
randomized to undergo bone marrow aspiration (n = 101) and subsequent intracoronary 
injection of autologous mBMC or to a placebo group (n = 103) that underwent the same 
procedures, but received intracoronary injection of a cell culture medium without mBMC. 
After 4 months a slight increase of LVEF (angiography) of 2.5 % could be demonstrated in 
favour of the mBMC group. However, in the control group LVEF increased only from 46.9% 
at baseline to 49.9% after 4 months, compared to the mBMC group where an increase from 
48.3% to 53.8% was noted. The improvement in LVEF in the control group in REPAIR-AMI 
is strikingly lower as  compared to the control groups in Janssens study and the ASTAMI trial 
(paper IV) and to what would be expected in patients with STEMI treated by PCI 192. The 
difference in improvement of LVEF after 4 months between the two groups in REPAIR-AMI 
could possibly be explained by a poor outcome in the control group. Anyway, an 
improvement in LVEF of 2.5% is small and would hardly influence on symptoms and 
survival.
So far, clinical trials have shown disappointing  results regarding improvement in left 
ventricular ejection fraction in patients with acute ST-elevation myocardial infarction treated 
with intracoronary injection of bone marrow cells 190-194.
The role of inflammation 
Several issues like underlying mechanisms for potential beneficial effects of stem cell 
transplantation, optimal cell type and number, timing after AMI, and delivery methods are not 
clarified. Cardiac transdifferentiation, paracrine effects, angiogenesis, and reduced apoptosis 
have been proposed as possible mechanisms for effects of mBMC, but are still to be proven 
195. The optimal timing for delivery of mBMC in AMI is probably dependent on the 
inflammatory environment. Several steps like attraction, transcapillary migration and 
invasion, as well as retention and survival in the infarcted area are essential for mBMC to 
exert their potential beneficial effects. Several critical steps like homing, engraftment, 
survival, differentiation and paracrine action of the mBMC are partly dependent on the 
inflammatory environment 138, 196-198.
Increased levels of inflammatory cytokines may reduce the survival of the injected mBMC as 
suggested by Suzuki et al. who showed improved survival of skeletal muscle precursor cells 
implanted in mouse hearts treated with anti-IL1E antibody 199, 200. The delivery method of 
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mBMC may also be of importance. As discussed in paper V, we found a marked short term 
pro-inflammatory response the day after intracoronary injection of mBMC that could be 
induced by the procedure per se. Induction of apoptosis by pro-inflammatory cytokines might 
reduce the number of stem cells in the infarct area and thus the potential benefit of cell 
transplantation 201. Bone marrow aspiration and intracoronary injection of mBMC may be an 
unfavourable method for treating patient with AMI by stem cells, because of the induction of 
a pro-inflammatory response that may have deleterious effects on the infarct process and 
vulnerable plaques in the coronary arteries, as well as reduced survival of the transplanted 
cells.
The optimal time for intracoronary injection of mBMC remains unknown, but is probably 
dependent on the balance between facilitating and detrimental cytokines of importance for 
homing and cell survival. Obviously, we need to go back to the bench and expand our 
knowledge about the role of mBMC in cardiac repair in patients with AMI.
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8  Conclusions 
The main conclusions in the present work can be summarized as follows: 
¾ Reduced  levels of pro-inflammatory markers were present in patients treated with 
      aspirin 160 mg daily compared to warfarin for up to 4 years after an acute myocardial           
      infarction. However, these findings were not reflected in the incidence of clinical end-
      points after 4 years. (Paper I) 
¾ In patients with stable coronary heart disease 1 year treatment with aspirin 160 mg daily 
and clopidogrel 75 mg daily induced similar reduction in the levels of TNFD and MCP-1 
(the latter only significant in the aspirin group), possibly by different mechanisms.          
(Paper II)
¾ In patients with acute ST-segment elevation myocardial infarction treated with PCI    
       a marked short term increase in circulating levels of IL-6 and CRP as well as of IL-10 
compared to similarly treated patients with stable angina pectoris appeared. The PCI 
procedure per se also induced an increase in IL-6 levels in patients with stable angina 
pectoris. The myocardial infarction induced a systemic inflammatory reaction that 
overwhelmed the inflammatory response induced by the PCI procedure. (Paper III). 
¾ No effects on global left ventricular function after 6 months were obtained in patients
      with acute myocardial infarction treated with intracoronary injection of autologous
      mBMC 6 days after acute PCI. (Paper IV) 
¾ In AMI patients treated with intracoronary injection of mBMC 6 days after the acute   
PCI a short-term pro-inflammatory response that may be unfavourable, and a slightly 
       reduced inflammatory response after 3 months that may be beneficial, were noted.               
(Paper V) 
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